Intraduction
============

Periprosthetic joint infection (PJI) due to *Brucella*is rare. We present a case of PJI due to *Brucella melitensis* and review the literature with respect to clinical presentation, diagnosis and treatment.

Case Report
===========

A 75-year-old man from Turkey presented with a six-months history of progressing knee pain. His personal history included total right knee arthroplasty (TKA) because of osteoarthritis 12 years prior to, and one stage exchange due to aseptic loosening 4 years prior to admission. On presentation, radiographs of the right knee showed loosening of the prosthesis with migration of the tibial component (Figure [1](#F1){ref-type="fig"}a, b). Before referral to our center, *B. melitensis* grew in synovial fluid specimen obtained via arthrocentesis.

The patient was born and raised in Turkey: He had moved to Switzerland at the age of 44. He reported to spend his summers in Turkey. There, he owns a house in a rural area, and commonly ingests fresh unpasteurized cheese and milk.

On presentation, he was afebrile and no episodes of fever or night sweats were reported. Blood tests showed a C-reactive protein (CRP) of 18 mg/l (norm \< 8 mg/l); leukocytes and thrombocytes were within normal range. Chest and lumbar radiographs, as well as abdominal ultrasound, were normal. Two sets of blood cultures remained negative. Serological test for antibodies against *Brucella* spp. were positive (IgG/IgA of 1:240 U/mL, normal \< 20 U/ml; Brucella IgG/M/A Serion ELISA classic, SERION^®^ Immunologics, Wuerzburg, Germany).

A combined antimicrobial therapy consisting of doxycycline 100 mg twice per day and intravenous (IV) gentamicin 5 mg/kg once daily was started one week prior to surgery. The surgical plan included a two-stage exchange with a short interval. After removal of the implant, a mobile antibiotic loaded spacer (containing gentamicin and vancomycin) was implanted. Surgery was carried out under aerosol isolation precautions and laboratory personnel were informed about possible risk of exposure. *B. melitensis* grew in 3, and *Propionibacterium acnes* in 4 out of 10 obtained biopsies, sonication was negative. Thus, penicillin was added to the regimen (24 million units IV divided in 6 doses per day). After 2.5 weeks, a revision TKA was implanted (LCS Revision®, DePuy Synthes, Warsaw, IN). The further clinical course was uneventful. In the postoperative period, treatment with rifampin 450 mg twice per day was added, and gentamicin discontinued. Because *P. acnes* proved to be susceptible to doxycycline, treatment with penicillin was stopped and continued with doxycycline plus rifampin. Three months after surgery, monotherapy with doxycycline for another three months was prescribed.

At the 2-year follow-up examination, the patient reported good joint function (ROM 0/5/105, WOMAC-Scale 12, VAS 80, EQ-5D 1) without clinical signs of infection. Radiographs showed a properly aligned TKA and no signs of loosening (Figure [1](#F1){ref-type="fig"}cd).

Review of the Literature
========================

Methods
-------

For identifying published case reports, PubMed, PMC and Scopus databases were searched using the search string "Brucell\* AND (prosth\* OR replacement OR arthroplasty) AND (knee OR hip OR joint)". Further a google query for "Brucella PJI" was performed. No restriction for time period of publications was applied. Two authors (DF and CS) reviewed titles and abstracts without restriction on date or language. Cases with symptoms consistent with PJI and *Brucella* spp. recovered from either synovial fluid culture or biopsy samples were included.

Results
=======

The literature screening procedure is illustrated in Figure [2](#F2){ref-type="fig"}. Twenty-five published articles describing 29 patients were identified [@B1]-[@B25] (Table [1](#T1){ref-type="table"}). Three of them were co-infections. Two articles describing the same patients were excluded [@B26], [@B27].

Most patients were male and originated from southern Europe (Spain, Portugal, Italy, Portugal, Greece), or the Middle East (Turkey, Israel, Lebanon, Iran, Saudi Arabia). The majority reported a history that was congruent with the pathogenesis (e.g., regular consumption of unpasteurized dairy products, occupational exposure to animals).

Eleven hip and 19 knee infections were described. The range of time interval between implantation of the prosthesis and the diagnosis of PJI was very broad (from immediately postoperative up to 168 months) with a median of 48 months. 62% (18/29) of patients had only local symptoms, and 38% (11/29) both systemic (mainly fever, malaise) and local symptoms. More than half of the patients (17/29) had a radiologically documented loosening of the implant. Twenty-three cases of *B. melitensis*, three of *B. abortus* and four cases of *Brucella*sp*.* were described. Diagnosis was mostly made by positive joint aspiration cultures (16/23). When no aspiration was performed (7/30) or aspiration culture was negative (7/23) intraoperative tissue biopsies were diagnostic. Only three cases had reported positive blood cultures. All cases with reported serology results revealed positive anti-Brucella antibodies (21/21). Three co-infections were documented, our case with*P. acnes*, one with viridans-group streptococci and one with *Acinetobacter baumanii.*In patients with radiological documented loosening, a one-stage exchange was performed in three, removal of the implant without replacement in one, and a two-stage exchange with a long interval (between 6 weeks and 6 months, median 8 weeks) in 12 cases. In twelve patients without implant loosening, eight patients were treated conservatively (i.e. without surgery), two had a debridement with retention of the prosthesis and one had a one-stage and two-stage exchange, respectively. The outcome of all patients was reported as good. However, a follow up of a year or more was reported in only 23/30 cases (maximal 10 years, median 2 years). Moreover, we cannot exclude a publication bias (i.e., only cases with a good outcome are reported). The antimicrobial regimen consisted of doxycycline and rifampin in most cases, with or without an aminoglycoside (streptomycin or gentamicin). In single cases quinolones or trimethoprim-sulfamethoxazole were used as a salvage treatment. The duration of antibiotic therapy varied markedly (median 16 weeks, range 6 weeks to 2 years) (Table [2](#T2){ref-type="table"}).

Discussion
==========

The preoperative diagnosis of *Brucella* PJI is a challenge in non-endemic countries, mainly because of the rarity of the disease, and hence, lack of clinical experience. The microbiological analyses of synovial fluid in patients with suspected PJI is part of the routine diagnostic procedure in many centers. In case of *Brucella* PJI, however, this intervention - without the required aerosol precautions - may expose personnel both in the operating room and microbiology laboratory to the pathogen [@B28]. In contrast, serological tests for brucellosis in previously untreated patients and in non-endemic region are reliable and safe diagnostic tools [@B29]. Our and all reported cases revealed significant elevated anti-*Brucella*-antibodies. Thus, it is conceivable to think of brucellosis and perform serological tests prior to synovial puncture, when the patient history (e.g., exposure to unpasteurized dietary products) or his ethnicity points towards this differential diagnosis.

In cases of suspected or confirmed *Brucella* PJI, infection control precautions are necessary prior to a surgical intervention. Laboratory staff must be pre-informed about potential growth of *Brucella* spp. when biopsy samples are sent for analyses [@B14], [@B28], [@B30]. Our literature review indicates that cultures of intra-operative tissue samples provide the best yield.

There is no uniform recommendation for the surgical procedure in *Brucella* PJI. Loose implants must be exchanged, and successful outcomes with both one-stage and two-exchanges have been reported. Although a wide range of time periods for the implant-free interval have been reported (i.e., 6 weeks to 6 months), we were unable to find a scientific rational against a short interval. Although, *Brucella* spp. have shown to form Biofilm in vitro [@B31], [@B32], to the best of our knowledge, there are no reports on *Brucella*-associated biofilm production on orthopedic implants. Thus, the clinical significance of *in-vitro* results requires further investigations. The overall good prognosis of *Brucella* PJI irrespective of applied treatment concept supported our surgical concept of a short interval.

Antimicrobial treatment for brucellosis requires a combination regimen, because high relapse rates have been reported with monotherapy. Rifampin, doxycycline, ciprofloxacin, trimethoprim-sulfamethoxazole and aminoglycosides have good activity against brucellosis. Antimicrobial drug resistance is unusual but can be determined by the Etest method [@B33]. Doxycycline plus streptomycin or doxycycline plus rifampin are the most commonly-used combinations [@B34]-[@B36]. Given the side effects of aminoglycosides, in particular in the elderly, we prefer not to use gentamicin or streptomycin for a prolonged treatment period.

It may be reasonable to start antimicrobial treatment prior to surgical intervention to lower the bacterial load, provided that *Brucella* spp. and other microorganisms are isolated from a preoperative joint puncture. In 10% of the described cases, a polymicrobial infection was reported. In retrospect, *P. acnes* may have been missed in our case.

The optimal treatment duration in *Brucella* PJI is unknown. In brucellosis, irrespective of infection site, less than 6 weeks with monotherapy is associated with failure [@B37]. In analogy to treatment recommendation for brucellar spondylitis, we targeted a combination therapy of at least 12 weeks [@B35].

Conclusions
===========

*Brucella* PJI is rare, and the diagnosis is often unexpected in non-endemic countries. Thinking of risk factors and ethnicity is the key to the diagnosis. Serological tests should be performed prior to joint puncture or surgical interventions. In case of positive anti-*Brucella*-antibodies, infection control must be involved and laboratory personnel informed prior to obtaining samples. Our review of the literature indicates that the prognosis is good, irrespective of surgical treatment modality. In rare cases, a polymicrobial infection can occur. On the basis of these data, and with respect to a shorter hospitalization period and better joint function, we prefer either a one-stage exchange or a two-stage exchange with a short interval in case of loose implants. A combination antimicrobial regimen is recommended, though, the optimal treatment duration is unknown. In our case, a 3-month course of doxycycline plus rifampin, followed by a 3 month-course of doxycycline monotherapy showed a successful outcome.
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###### 

Demographics and diagnostics

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Patient No   Demographics   Country of\                    Involved\           Age of PJ\      Previous\   Symptoms   Cultures             Brucella          References                           
                              Exposure                       Prosthesis          (months)        Revisions                                                                                          
  ------------ -------------- ------------------------------ ------------------- --------------- ----------- ---------- -------------------- ----------------- ------------ ----- ----- ----- ----- -----------
  **1**        24, f          na                             Saudi Arabia        TKR bilateral   2           no         local symptoms       *B. melitensis*   pos          na    na    no    pos   1

  **2**        72, m          unpasteurized dairy products   Turkey              TKR             48          no         local symptoms       *B. melitensis*   na           pos   neg   no    pos   2 (27)

  **3**        50, m          farmer, cattle                 Spain               THR             0           no         systemic and local   *B. melitensis*   na           pos   pos   no    pos   3

  **4**        71, m          farmer, cattle                 Spain               THR             36          no         local symptoms       *B. melitensis*   na           pos   na    yes   na    3

  **5**        67, f          na                             Mexico              THR             24          no         local symptoms       *B. abortus*      neg          pos   na    no    na    4 (26)

  **6**        65, f          unpasteurized dairy products   Portugal            TKR bilateral   na          no         systemic and local   *B. melitensis*   neg          pos   na    no    na    5

  **7**        63, f          unpasteurized dairy products   Turkey              TKR             24          yes        systemic and local   *B. melitensis*   neg          pos   neg   no    pos   6

  **8**        71, f          na                             Spain               TKR             48          no         systemic and local   *Brucella sp*     pos          na    na    no    pos   7

  **9**        68, f          na                             Iran                TKR             12          no         local symptoms       *Brucella sp*     neg          pos   na    no    na    8

  **10**       54, m          farmer                         United States       THR             6           no         systemic and local   *B. abortus*      neg          pos   na    no    pos   9

  **11**       62, m          na                             Turkey              TKR             24          no         systemic and local   *B. melitensis*   pos          na    na    no    pos   10

  **12**       47, m          unpasteurized dairy products   Lebanon             THR             168         no         local symptoms       *Brucella sp*     na           pos   na    no    pos   11

  **13**       79, m          contact with cattle            Israel/ Argentina   TKR             144         no         local symptoms       *B. melitensis*   na           pos   na    no    na    12

  **14**       51, m          contact with goats             Thailand            TKR             60          no         systemic and local   *B. melitensis*   pos          na    pos   no    pos   13

  **15**       na             unpasteurized dairy products   India               THR             na          na         na                   *B. melitensis*   pos          na    na    na    na    14

  **16**       74, m          shepherd                       Greece              TKR bilateral   4           no         systemic and local   *B. melitensis*   pos          na    pos   no    pos   15

  **17**       67, f          unpasteurized dairy products   Italy               TKR bilateral   48          no         local symptoms       *Brucella sp*     neg          pos   na    no    na    16

  **18**       74, m          unpasteurized dairy products   Italy               TKR             108         no         local symptoms       *B. melitensis*   na           pos   na    no    pos   17

  **19**       65, f          na                             Turkey              TKR bilateral   96          no         systemic and local   *B. melitensis*   pos          na    na    no    pos   18

  **20**       63, m          contact with cattle            Spain               THR             60          no         local symptoms       *B. melitensis*   pos          pos   neg   no    na    19

  **21**       60, m          contact with goats             Spain               TKR             14          no         local symptoms       *B. melitensis*   pos          na    neg   no    pos   20

  **22**       66, f          contact with cattle            Spain               THR             36          no         local symptoms       *B. abortus*      pos          na    na    no    na    21

  **23**       71, m          farmer, cattle                 Spain               THR             63          yes        local symptoms       *B. melitensis*   na           pos   na    no    pos   21

  **24**       68, m          na                             Italy               TKR             24          no         local symptoms       *B. melitensis*   pos          na    na    no    pos   22

  **25**       56, m          farmer, sheep                  Spain               THR             60          no         systemic and local   *B. melitensis*   pos          na    neg   no    pos   23

  **26**       38, m          unpasteurized dairy products   Israel              THR             48          no         local symptoms       *B. melitensis*   neg          pos   na    no    pos   24

  **27**       61, m          unpasteurized dairy products   Israel              TKR             36          yes        local symptoms       *B. melitensis*   pos          pos   na    yes   pos   24

  **28**       67, m          unpasteurized dairy products   Israel              TKR             168         no         systemic and local   *B. melitensis*   pos          na    na    no    pos   24

  **29**       64, f          unpasteurized dairy products   Turkey              TKR             60          no         local symptoms       *B. melitensis*   pos          na    na    no    pos   25

  **30**       75, m          unpasteurized dairy products   Turkey              TKR             144         yes        local symptoms       *B. melitensis*   pos          pos   neg   yes   pos   this case
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**\***Serum agglutination (=standard tube agglutination (SAT)) was used in most cases. Only positive results were quoted because of limited comparability among the different tests used**; THR**total hip replacement**; TKR**total knee replacement**; PJ**prosthetic joint**; na**not available.

###### 

Treatment and follow-up.

  ---------------------------------------------------------------------------------------------------------------------------------------------------
  Patient No   Implant\    Surgical\            Implant-free\      Antimicrobial Treatment\                       Good\     Follow-up\   \
               Loosening   Treatment            Interval (weeks)   and Duration (weeks)                           outcome   (years)      References
  ------------ ----------- -------------------- ------------------ ---------------------------------------------- --------- ------------ ------------
  **1**        no          none                                    Dox/Rif 76w                                    yes       1.5          1

  **2**        no          DAIR (arthroscopy)                      Dox/Rif 6wk                                    yes       1            2 (27)

  **3**        no          none                                    Strep(2w)/Dox 106w                             yes       5            3

  **4**        yes         one-stage exchange                      Strep(1.5w)/Doxy/Rifa 25.5 w                   yes       3            3

  **5**        yes         two-stage exchange   24                 Dox/Rif 20w                                    yes       2            4 (26)

  **6**        yes         two-stage exchange   6                  Dox/Rif 12 w                                   yes       10           5

  **7**        no          none                                    Dox/Rif 16w                                    yes       3            6

  **8**        no          none                                    Dox/Rif 6.5w; then Strep(3w)/Dox 12w           yes       \<1          7

  **9**        no          two-stage exchange   24                 na                                             na        na           8

  **10**       no          one-stage exchange                      Tet 6w, then Tet 24w, then Strep(6w)/Tet 58w   yes       2            9

  **11**       yes         two-stage exchange   12                 Dox/Rif 12w                                    yes       10           10

  **12**       yes         one-stage exchange                      Dox/Rif 20w                                    yes       4            11

  **13**       yes         two-stage exchange   8                  Gen(3w)/Dox/Rif 25w, then Dox/Rif/Bact \>52w   yes       \<1          12

  **14**       no          none                                    Gen(2w)/Dox/Rif 24w                            yes       1            13

  **15**       na          na                                      na                                             na        na           14

  **16**       no          none                                    Strep(3w)/Dox 20w, then Bact 8w                yes       2            15

  **17**       yes         two-stage exchange   12                 Dox/Rif 12 w                                   yes       1.5          16

  **18**       yes         Implant removal                         Strep/Dox 4w, then Dox/Rif/Levo 32w            yes       \< 1         17

  **19**       yes         two-stage exchange   20                 Dox/Rif 16w                                    yes       2            18

  **20**       yes         two-stage exchange   16                 Strep/Dox/Rif 12w                              yes       \<1          19

  **21**       no          none                                    Strep/Dox/Rif 6w                               yes       \<1          20

  **22**       yes         two-stage exchange   16                 Dox/Rif 6w                                     yes       5.5          21

  **23**       no          DAIR                                    Strep(6w)/Dox/Rif 24w                          yes       5            21

  **24**       no          none                                    Dox/Rif 8w                                     yes       1            22

  **25**       yes         two-stage exchange   8                  Strep(2w)/Dox/Rif 8w                           yes       4            23

  **26**       yes         two-stage exchange   6                  Dox/Rif 12 w                                   yes       1            24

  **27**       yes         two-stage exchange   6                  Dox/Rif 12 w                                   yes       1            24

  **28**       yes         two-stage exchange   6                  Dox/Rif 12 w                                   yes       1            24

  **29**       yes         one-stage exchange                      Dox/Rif 24 w                                   yes       1.5          25

  **30**       yes         two-stage exchange   2.5                Dox/Rif/Pen 24w                                yes       2            this case
  ---------------------------------------------------------------------------------------------------------------------------------------------------

**Strep:**Streptomycin**; Gen:**Gentamicin;**Dox:**Doxycycline**; Rif:**Rifampin**; Bact:**Trimethoprim-Sulfamethoxazole**; Levo:**Levofloxacin**; Tet:**Tetracycline**; Pen:**Penicillin G**; DAIR:**debridement, antibiotics, irrigation and retention.
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